Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients.

Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients.

Publication date: Mar 29, 2024

Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.

Open Access PDF

Concepts Keywords
Immunometabolic Antigen
Months Cov
Mrna Cytometry
Scarce Dose
Sclerosis Efficacy
Functional
Immune
Metabolic
Mrna
Multiple
Patients
Sars
Sclerosis
Specific
Vaccine

Semantics

Type Source Name
disease VO vaccine efficacy
disease MESH multiple sclerosis
drug DRUGBANK Dimethyltryptamine
disease VO dose
disease VO vaccine
disease IDO cell
drug DRUGBANK Cladribine
drug DRUGBANK Dimethyl fumarate
drug DRUGBANK Fingolimod
drug DRUGBANK Natalizumab
drug DRUGBANK Teriflunomide
drug DRUGBANK Rituximab
drug DRUGBANK Ocrelizumab
disease IDO immune response
disease MESH sclerosis
disease MESH infections
disease VO vaccine effectiveness
disease IDO host
drug DRUGBANK Glatiramer
drug DRUGBANK Acetate ion
disease MESH lymphopenia
disease MESH diphtheria
drug DRUGBANK Clostridium tetani toxoid antigen (formaldehyde inactivated)
drug DRUGBANK keyhole limpet hemocyanin
disease VO Optaflu
disease MESH influenza
disease VO vaccination
disease VO immunization
drug DRUGBANK Ofatumumab
drug DRUGBANK Alemtuzumab
disease VO vaccinated
disease VO effectiveness
disease MESH COVID 19
drug DRUGBANK Sphingosine
drug DRUGBANK Phosphate ion
disease VO effective
disease IDO production
drug DRUGBANK Coenzyme M
disease VO Comirnaty
disease VO vaccination dose
disease IDO infection
drug DRUGBANK Methionine
disease MESH Relapsing Remitting Multiple Sclerosis
disease IDO history

Original Article

(Visited 1 times, 1 visits today)